Totally agree with you Moranpicks. Having been a 20+ year holder of CELG and a 10+ holder of BMY I can't think of a better transaction on the Street for BMY.
BMY is stealing CELG for a number of reasons that have nothing to do with the CELG Pipeline, which just received a FDA Priority Review for it's Fedratinib Drug application in Myelofibrosis filed in Dec 2018. Just a part of the future CELG pipeline. And REV is not going away. A cash cow that makes this a fully accretive transaction for BMY.
BMY needs CELG more that CELG needs BMY. I see nothing but positives for BMY despite the usual Street noise.